The Belgian drugmaker has presented positive data on its two submission-ready generalized myasthenia gravis drugs zilucoplan and rozanolixizumab but analysts are concerned that their efficacy will not differentiate them sufficiently to challenge Vyvgart and Soliris/Ultomiris.
UCB S.A. has presented more data on zilucoplan and rozanolixizumab, two late-stage therapies for generalized myasthenia gravis (gMG) but observers are sceptical about the pair's prospects of challenging the new drug on that particular rare disease block, argenx N.V.'s Vyvart.
The Belgian firm has unveiled detailed results from two Phase III trials of the two drugs for gMG, which causes...
Oral RNA splicing modulator has gone into a Phase II/III trial
With two deaths in non-ambulatory DMD patients, Sarepta is attempting damage control and will ask the US FDA to advise, setting up a possible confrontation with CBER director Prasad.
First results for a first-in-class mutCALR-targeted therapy in essential thrombocythemia presented at EHA point to a lucrative future for the early-stage product.
The oral BTK inhibitor impresses in a Phase II trial for IgG4-related disease.
The China Securities Regulatory Commission has proposed a new “growth tier” for the STAR Market of the Shanghai Stock Exchange, to reinstate the market’s listing standards for unprofitable firms.
Highlights from Day Four of the BIO International Convention include Woodcock offering practical advice on rare disease trials, the sorry state of dealmaking mid-year, Novartis discussing its approach to partnering, and Generate looking for funding to move into Phase III.
While some are calling for Syncona to be wound up, the UK-based company believes many existing and new investors will back the creation of new private fund.
